LDHA and colorectal cancer: A study of tissues from 179 colorectal cancer patients showed that patients treated with an anti‐angiogenic drug (Vatalanib) and cytotoxic chemotherapy [oxaliplatin/5‐fluorouracil (FOLFOX) (Bayer Schering Pharma AG, Berlin; Novartis, East Hanover, NJ, USA)] combination had an improved response rate and progression‐free survival if their tumor expressed elevated LDHA compared to patients with tumors expressing low levels of LDHA 66.